Arcturus Therapeutics Holdings Inc. (ARCT)

Clinical-stage mRNA medicines company focused on infectious diseases and vaccines.

ARCT Stock Quote

Symbol: ARCT
Quote: 12.81
Change: -0.01
Change %: -0.08%
High: 12.87
Low: 12.38
Open: 12.55
Volume: 272,394
52 Week: 8.04-45.00
P/E Ratio: -4.27
EPS: -3.00
Market Cap: 347.40 M

Company Report

Arcturus Therapeutics Holdings Inc. operates as an advanced-stage clinical biotechnology company specializing in mRNA medicines and vaccines. Founded in 2013 and headquartered in San Diego, California, Arcturus leverages cutting-edge technologies including LUNAR lipid-mediated delivery, STARR mRNA Technology (samRNA), and mRNA drug substance manufacturing.

The company's robust pipeline encompasses RNA therapeutic and vaccine candidates, notably including programs for SARS-CoV-2 (COVID-19) and Influenza. Additionally, Arcturus is advancing treatments for ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type III, and hepatitis B virus through strategic partnerships.

Arcturus' versatile RNA platforms support a range of nucleic acid medicines such as messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. This technological diversity is bolstered by a robust patent portfolio covering its innovations across key global markets including the U.S., Europe, Japan, and China.

Driven by a commitment to scientific excellence and innovation, Arcturus Therapeutics continues to push the boundaries of mRNA-based therapies. By advancing transformative treatments for infectious diseases and genetic disorders, the company aims to improve healthcare outcomes globally and make significant contributions to the field of biotechnology.

ARCT EPS Chart

ARCT Revenue Chart

Stock Research

HLT WTBA BMEA UCAR PFG PBI AOMR

ARCT Chart

View interactive chart for ARCT

ARCT Profile

Exchange: NASDAQ
Beta: 3.414
Industry: Biotechnology
Sector: Healthcare
Employees: 174
IPO Date: May 22, 2013

ARCT News

Article Image

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial re...

8 days ago
Article Image

The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

19 days ago
Article Image

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Ch...

1 months ago
Article Image

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.

1 months ago
Article Image

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth ...

1 months ago

Analyst Ratings